GSK マネジメント

マネジメント基準チェック /44

GSKの CEO はEmma Walmsleyで、 Apr2017年に任命され、の在任期間は 8.08年です。の年間総報酬は£ 10.56Mで、 12.9%給与と87.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.06%を直接所有しており、その価値は$ 46.64M 。経営陣と取締役会の平均在任期間はそれぞれ6.2年と3.1年です。

主要情報

Emma Walmsley

最高経営責任者

UK£10.6m

報酬総額

CEO給与比率	12.91%
CEO在任期間	8.1yrs
CEOの所有権	0.06%
経営陣の平均在職期間	6.2yrs
取締役会の平均在任期間	3.1yrs

経営陣の近況

Recent updates

CEO報酬分析

GSK の収益と比較して、Emma Walmsley の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2025	n/a	n/a	UK£3b
Dec 31 2024	UK£11m	UK£1m	UK£3b
Sep 30 2024	n/a	n/a	UK£3b
Jun 30 2024	n/a	n/a	UK£4b
Mar 31 2024	n/a	n/a	UK£4b
Dec 31 2023	UK£13m	UK£1m	UK£5b
Sep 30 2023	n/a	n/a	UK£6b
Jun 30 2023	n/a	n/a	UK£5b
Mar 31 2023	n/a	n/a	UK£4b
Dec 31 2022	UK£8m	UK£1m	UK£4b
Sep 30 2022	n/a	n/a	UK£3b
Jun 30 2022	n/a	n/a	UK£4b
Mar 31 2022	n/a	n/a	UK£4b
Dec 31 2021	UK£8m	UK£1m	UK£3b
Sep 30 2021	n/a	n/a	UK£4b
Jun 30 2021	n/a	n/a	UK£4b
Mar 31 2021	n/a	n/a	UK£5b
Dec 31 2020	UK£7m	UK£1m	UK£5b
Sep 30 2020	n/a	n/a	UK£6b
Jun 30 2020	n/a	n/a	UK£7b
Mar 31 2020	n/a	n/a	UK£5b
Dec 31 2019	UK£8m	UK£1m	UK£5b
Sep 30 2019	n/a	n/a	UK£5b
Jun 30 2019	n/a	n/a	UK£4b
Mar 31 2019	n/a	n/a	UK£4b
Dec 31 2018	UK£6m	UK£1m	UK£4b

報酬と市場: Emmaの総報酬 ($USD 14.29M ) は、 US市場 ($USD 14.24M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Emmaの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Emma Walmsley (55 yo)

8.1yrs

在職期間

UK£10,559,000

報酬

Dame Emma Natasha Walmsley serves as an Independent Director of Microsoft Corp. since December 4, 2019. She serves as Chief Executive Officer of GSK plc since April 1, 2017. Dame Walmsley served as the Chi...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Emma Walmsley	CEO & Director	8.1yrs	UK£10.56m	0.060% $ 46.6m
Julie Brown	CFO & Executive Director	2.1yrs	UK£4.17m	0.0042% $ 3.3m
Jesse Goodman	Scientific & Medical Expert	no data	UK£182.11k	0.00076% $ 594.9k
Shobie Ramakrishnan	Chief Digital & Technology Officer	4.3yrs	データなし	データなし
Tony Wood	Chief Scientific Officer and Head of R&D	2.8yrs	データなし	データなし
James Ford	Senior VP & Group General Counsel of Legal & Compliance	6.8yrs	データなし	データなし
Sally Jackson	Senior VP of Global Communications & CEO Office	6.2yrs	データなし	データなし
David Redfern	President of Corporate Development	no data	データなし	データなし
Diana Conrad	Chief People Officer	6.1yrs	データなし	データなし
Philip Thomson	President of Global Affairs	8.1yrs	データなし	0.0068% $ 5.3m
Luke Miels	Chief Commercial Officer	7.7yrs	データなし	データなし
Regis Simard	President of Global Supply Chain	no data	データなし	データなし

6.2yrs

平均在職期間

56.5yo

平均年齢

経験豊富な経営陣: GSKの経営陣は経験豊富で経験豊富です（平均在職期間は6.2年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Emma Walmsley	CEO & Director	8.3yrs	UK£10.56m	0.060% $ 46.6m
Julie Brown	CFO & Executive Director	2yrs	UK£4.17m	0.0042% $ 3.3m
Jonathan Symonds	Non-Executive Chairman	5.7yrs	UK£781.00k	0.0021% $ 1.6m
Vishal Sikka	Independent Non-Executive Director	2.8yrs	UK£137.38k	0.00045% $ 352.2k
Hal Barron	Non-Executive Director	7.3yrs	UK£369.02k	0.033% $ 25.9m
Harry Dietz	Independent Non-Executive Director	3.3yrs	UK£219.65k	0.00019% $ 148.7k
Anne Beal	Independent Non-Executive Director	4yrs	UK£203.68k	0.00020% $ 156.6k
Wendy Mira Becker	Independent Non-Executive Director	1.6yrs	UK£157.00k	0.000070% $ 54.8k
Charles Bancroft	Senior Independent Non-Executive Director	5yrs	UK£265.98k	0.0016% $ 1.3m
Gavin Screaton	Independent Non-Executive Director	no data	データなし	0.00021% $ 164.4k
Tsun-Huei Lee	Scientific & Medical Expert and Independent Non-Executive Director	1.2yrs	UK£132.59k	0.000050% $ 39.1k
Elizabeth Anderson	Independent Non-Executive Director	2.7yrs	UK£164.54k	0.00012% $ 93.9k

3.1yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: GSKの取締役会は経験豊富であると考えられます ( 3.1年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/05/23 11:40
終値	2025/05/23 00:00
収益	2025/03/31
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

GSK plc 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。69

アナリスト	機関
Kamla Singh	AlphaValue
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research

GSK マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

GSK plc, Annual General Meeting, May 07, 2025

GSK plc Announces Board and Committee Changes

Recent updates

GSK plc Announces Blenrep (Belantamab Mafodotin) Combination Receive Positive CHMP Opinion in Relapsed/Refractory Multiple Myeloma

GSK plc Announces Approval Ofenrep Combinations by Japan's Ministry of Health, Labour and Welfare for the Treatment of Adults with Relapsed/Refractory Multiple Myeloma

GSK plc (LSE:GSK) agreed to acquire Efimosfermin alfa drug from Boston Pharmaceuticals Inc. for $2 billion.

GSK plc Announces Positive Results for Nucala

GSK plc Announces the Authorisation of Blenrep by the Medicines and Healthcare Products Regulatory Agency

GSK plc Recommends the Use of RSV Vaccines Including GSK'sAREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)

GSK plc to Report Q1, 2025 Results on Apr 30, 2025

GSK's Omjjara (Momelotinib) Approves in Singapore as the First Treatment Indicated for Myelofibrosis Patients with Anaemia

GSK plc, Annual General Meeting, May 07, 2025

US Food and Drug Administration Accepts Depemokimab Application for the Use of D Epemokimab in Two Indications

GSK plc (LSE:GSK) announces an Equity Buyback for £2,000 million worth of its shares.

GSK plc (LSE:GSK) completed the acquisition of IDRX, Inc. from a group of shareholders.

GSK plc Announces That The Chinanational Medical Products Administration Has Accepted for Review the New Drug Application for the Use of Nucala (Mepolizumab)

GSK plc Announces Board and Committee Changes

GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'

Gsk plc Announces Approval of Penmenvy, Gsk’S 5-In-1 Meningococcal Vaccine by US FDA

GSK Reported Strong Earnings, So I Reiterate My Strong Buy

GSK plc Provides Earnings Guidance for the Full-Year of 2025; Provides Earning Guidance for 2026

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against GSK plc

GSK plc Announces Acceptancy of Depemokimab Applications for Review in China and Japan for Asthma with Type 2 Inflammation and CRSwNP

Gsk plc Announces the European Medicines Agency Accepts for Review the Regulatory Application of A Prefilled Syringe Presentation of Shingrix

GSK plc Announces the European Commission Approval to Expand the Use of Jemperli Plus Chemotherapy (Caroplatin and Paclitaxel) for First-Line Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Cancer

GSK plc to Report Q4, 2024 Results on Feb 05, 2025

GSK plc (LSE:GSK) entered into an agreement to acquire IDRX, Inc. from a group of shareholders for approximately $1.2 billion.

Us Food and Drug Administration Accepts GSK Plc's Shingrix New Prefilled Syringe Presentation of Shingrix for the Prevention of Shingles (Herpes Zoster)

GSK Gets FDA Breakthrough Therapy Designation for GSK5764227

Gsk Plc's B7-H3-Targeted Antibody-Drug Conjugate, Gsk'227, Receives US Fda Breakthrough Therapy Designation in Late-Line Relapsed or Refractory Osteosarcoma

GSK plc's Nucala (Mepolizumab) Approves in China for Treatment of Adults with Chronic Rhinosinusitis with Nasal Polyps

GSK plc Announces First Trial Met Its Primary Endpoint of Progression Free Survival in First Line Advanced Ovarian Cancer

GSK plc's Jemperli (dostarlimab) Receives US FDA Breakthrough Therapy Designation for Locally Advanced dMMR/MSI-H Rectal Cancer

GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade

GSK plc Announces Results from Planned Interim Analysis of the DREAMM-7 Trial Evaluating Belantamab Mafodotin in Combination with Bortezomib Plus Dexamethasone

GSK plc Announces Blenrep Combination China Filing Acceptance

Gsk Plc's Fully Liquid Menveo Meningococcal Vaccine Approves by European Commission

Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (Pbc)

GSK plc Announces Overall Survival Results for Blenrep

GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'

GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk

GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2

Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results

GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine

Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion

GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell

GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme

GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon

GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial

GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK's Q2 Success Amid Challenges: What Investors Need To Know

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

GSK: Good Earnings Report, But Risks Ahead (Rating Downgrade)

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

GSK plc (LSE:GSK) completed the acquisition of BELLUS Health Inc. (TSX:BLU).

CEO報酬分析

CEO

リーダーシップ・チーム

取締役

マネジメント基準チェック /44